ImCheck Therapeutics today announced that it will present updated data from its Phase I/IIa clinical trial EVICTION-2 in a poster presentation at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting 2023. In EVICTION-2, ImCheck’s lead program, ICT01, a humanized anti-BTN3A monoclonal antibody that selectively activates γ9δ2 T cells, is evaluated in combination with lose dose IL-2 on its ability to increase the number of γ9δ2 T cells and boost the anti-tumor immune response in patients with advanced-stage solid tumors. The conference will be held November 3-5 in San Diego, USA.
Details of the poster presentation are:
Abstract title: “ICT01 plus Low Dose SC IL-2 Produces a Robust Anti-Tumor Immune Activation in Advanced Cancer Patients (EVICTION-2 Study)”
Session title: Clinical Trials in Progress
Abstract number: 715
Authors: Johann de Bono, Stéphane Champiat, Francois-Xavier Danlos, Martin Wermke, Volker Kunzmann, Aude De Gassart, Emmanuel Valentin, Marina Iché, Maelle Mairesse, Patrick Brune, Katrien Lemmens, Daniel Olive, Paul Frohna
Location: Exhibit Halls A and B1 – San Diego Convention Center
Date/Time: Friday, Nov. 3, 2023; 12:00–1:30 pm and 5:10–6:40 pm